Transdermal NO Formulation for Bioavailability and Vascular Integrity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing delivery methods for therapeutic agents face bioavailability issues due to low solubility, poor uptake from the gut, and rapid elimination by the liver, leading to inadequate systemic or local therapeutic levels at targeted sites, particularly for agents like nitric oxide (NO) that are crucial for preventing and treating endothelial dysfunction.
Innovation Solution
A transdermal formulation comprising an NO booster and/or precursor, solvent, and optionally a fatty acid, which enhances systemic NO levels by boosting production or releasing NO directly into the circulation, while reducing reactive oxygen species (ROS) production, thereby restoring vascular health and integrity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If oral or IV routes of administration are used to deliver therapeutic agents, then systemic delivery is achieved, but adequate therapeutic levels at the targeted local site are not provided due to poor bioavailability
Solution Approach 1:
The patent uses the skin and transdermal delivery system as an intermediary route to bypass the problematic gastrointestinal and hepatic first-pass metabolism pathways. The transdermal formulation delivers nitric oxide donors directly through the skin into systemic circulation, avoiding the unreliable oral/IV absorption and liver metabolism that prevent adequate therapeutic levels from reaching target sites.
Solution Approach 2:
The patent replaces the conventional oral/IV mechanical delivery systems with a transdermal delivery mechanism. Instead of relying on gastrointestinal absorption and hepatic processing, the invention uses transdermal penetration of nitric oxide donors to achieve reliable systemic delivery and local therapeutic effects at target sites.
2Reliability
If nitric oxide is systemically delivered to enhance NO levels in the vasculature, then endothelial dysfunction is reversed, but the short lifetime of the NO molecule and limited access to the circulation prevent effective delivery
Solution Approach 1:
The patent applies preliminary action by using transdermal delivery to pre-establish sustained systemic circulation of nitric oxide donors before they can be rapidly eliminated. The transdermal route provides continuous delivery that compensates for the short half-life of nitric oxide, maintaining therapeutic levels in the vasculature despite the molecule's rapid degradation.
Solution Approach 2:
The patent implements continuity of useful action through sustained transdermal delivery of nitric oxide donors. Instead of intermittent dosing that would allow rapid elimination to occur, the transdermal formulation provides continuous release and delivery of nitric oxide to the circulation, maintaining constant therapeutic levels despite the short lifetime of the NO molecule.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation effectively enhances systemic NO levels, restores vascular integrity, and prevents or reverses endothelial dysfunction, offering treatments for various conditions including inflammatory diseases, endothelial dysfunction, and oxidative damage.
Implementation Method 1
Sustained transdermal systemic delivery can also be achieved to harness therapeutic potential of NO for various chronic diseases and conditions
Implementation Method 2
the NO precursor comprises an NO releasing agent or derives or produces a NO releasing agent
Implementation Method 3
limit the production of reactive oxygen species
Data Source
AI summary
A transdermal formulation for the delivery of a nitric oxide booster or nitric oxide precursor to a subject is provided. The formulation can be applied to the treatment of various diseases or conditions by enhancing systemic level of nitric oxide.